UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 122

Sortiert nach

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Emerging infectious diseases, 2020-08, Vol.26 (8), p.1792-1800

2020

Link zum Volltext

Verfügbarkeit prüfen

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Microbiology spectrum, 2022-10, Vol.10 (5), p.e0192222-e0192222

2022

Link zum Volltext

Verfügbarkeit prüfen

Weighted log‐rank test to compare two survival functions in the presence of dependent censoring

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2022-11, Vol.21 (6), p.1281-1293

Flandre, Philippe

2022

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Clinical journal of the American Society of Nephrology, 2011-07, Vol.6 (7), p.1700-1707

2011

Link zum Volltext

Verfügbarkeit prüfen

Choice of effect measure in HIV randomized trials

AIDS (London), 2015-09, Vol.29 (15), p.2057-2060

Flandre, Philippe

2015

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2064

2022

Link zum Volltext

Verfügbarkeit prüfen

Note on the role of the placebo group in the short‐term and long‐term hazard ratio model

Statistics in medicine, 2020-09, Vol.39 (20), p.2685-2688

2020

Link zum Volltext

Verfügbarkeit prüfen

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Link zum Volltext

Verfügbarkeit prüfen

Some current issues in the design of HIV noninferiority trials

AIDS (London), 2014-08, Vol.28 (13), p.1921-1929

FLANDRE, Philippe

2014

Link zum Volltext

Verfügbarkeit prüfen

Design of HIV noninferiority trials: where are we going?

AIDS (London), 2013-02, Vol.27 (4), p.653-657

FLANDRE, Philippe

2013

Link zum Volltext

Verfügbarkeit prüfen

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2934-2939

2009

Link zum Volltext

Verfügbarkeit prüfen

Weighted Kaplan‐Meier estimators motivating to estimate HIV‐1 RNA reduction censored by a limit of detection

Statistics in medicine, 2020-03, Vol.39 (7), p.968-983

2020

Link zum Volltext

Verfügbarkeit prüfen

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3237-3243

2008

Link zum Volltext

Verfügbarkeit prüfen

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Antimicrobial Agents and Chemotherapy, 2010-11, Vol.54 (11), p.4910-4913

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Antimicrobial Agents and Chemotherapy, 2005-05, Vol.49 (5), p.1739-1744

2005

Link zum Volltext

Verfügbarkeit prüfen

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Antimicrobial Agents and Chemotherapy, 2008-02, Vol.52 (2), p.491-496

2008

Link zum Volltext

Verfügbarkeit prüfen

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31

2011

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of predictive ability measures for survival models

Statistics in medicine, 2017-09, Vol.36 (20), p.3171-3180

2017

Link zum Volltext

Verfügbarkeit prüfen

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The American statistician, 2021-10, Vol.75 (4), p.376-382

2021

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of predictive ability measures for survival models: P. FLANDRE, R. DEUTSCH AND J. O'QUIGLEY

Statistics in medicine, 2017-09, Vol.36 (20), p.3171-3180

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Journal of Virology, 2005-08, Vol.79 (15), p.9572-9578

2005

Link zum Volltext

Verfügbarkeit prüfen

Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4251-4257

2008

Link zum Volltext

Verfügbarkeit prüfen

Comparing Kaplan–Meier curves with delayed treatment effects: applications in immunotherapy trials

Journal of the Royal Statistical Society Series C: Applied Statistics, 2019-08, Vol.68 (4), p.915-939

2019

Link zum Volltext

Verfügbarkeit prüfen

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44

2019

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir and changes in renal function

AIDS (London), 2010-02, Vol.24 (4), p.619-620

Flandre, Philippe

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 122

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos One

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(122)

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(91)
Humans
(85)
Infectious Diseases
(71)
Hiv Infections - Drug Therapy
(59)
Medical Sciences
(53)
Biological And Medical Sciences
(52)
Male
(48)
Female
(43)
Virology
(42)
Hiv Infections - Virology
(40)
Microbiology
(36)
Adult
(34)
Hiv-1 - Genetics
(34)
Hiv-1 - Drug Effects
(33)
Pharmacology. Drug Treatments
(33)
Viral Diseases
(33)
Viral Load
(33)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(32)
Human Viral Diseases
(32)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Weighted log‐rank test to compare two survival functions in the presence of dependent censoring

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Choice of effect measure in HIV randomized trials

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Note on the role of the placebo group in the short‐term and long‐term hazard ratio model

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Some current issues in the design of HIV noninferiority trials

Design of HIV noninferiority trials: where are we going?

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Weighted Kaplan‐Meier estimators motivating to estimate HIV‐1 RNA reduction censored by a limit of detection

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Accuracy of predictive ability measures for survival models

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

Accuracy of predictive ability measures for survival models: P. FLANDRE, R. DEUTSCH AND J. O'QUIGLEY

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials

Comparing Kaplan–Meier curves with delayed treatment effects: applications in immunotherapy trials

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Tenofovir and changes in renal function

Aktive Filter

Suchergebnisse filtern